Late-onset neuromyelitis optica spectrum disorder in AQP4-seropositivepatients in a Chinese population

BMC Neurology

Volumn 15, Issue 1, 2015, Pages

  Mao, Zhifeng ^a   Yin, Junjie ^a   Zhong, Xiaonan ^a   Zhao, Zhihua ^a   Qiu, Wei ^a   Lu, Zhengqi ^a   Hu, Xueqiang ^a  

^a THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AQUAPORIN 4 ANTIBODY; ANTIBODY; AQUAPORIN 4;

ADULT; AGED; ARTERY THROMBOSIS; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CHINESE; CLINICAL ARTICLE; CLINICAL FEATURE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DEMOGRAPHY; DIABETES MELLITUS; DISEASE SEVERITY; EARLY ONSET NEUROMYELITIS OPTICA SPECTRUM DISORDER; EXPANDED DISABILITY STATUS SCALE; FEMALE; FOLLOW UP; GENDER; HUMAN; HYPERTENSION; LATE ONSET NEUROMYELITIS OPTICA SPECTRUM DISORDER; LONGITUDINALLY EXTENSIVE TRANSVERSE MYELITIS; MALE; MEDICAL RECORD REVIEW; MYELITIS; MYELOOPTIC NEUROPATHY; NEUROIMAGING; ONSET AGE; OPTIC NEURITIS; OSTEOPOROSIS; OUTCOME ASSESSMENT; PROGNOSIS; SYMPTOM; VEIN THROMBOSIS; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD; CHINA; IMMUNOLOGY; MIDDLE AGED; NEUROMYELITIS OPTICA; RETROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX;

AGE OF ONSET; AGED; ANTIBODIES; AQUAPORIN 4; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; COHORT STUDIES; COMORBIDITY; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; NEUROMYELITIS OPTICA; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 84940775914     PISSN: None     EISSN: 14712377     Source Type: Journal    
DOI: 10.1186/s12883-015-0417-y     Document Type: Article

References (23)

1. Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med. 2005;202:473-7.
2. Saadoun S, Waters P, Bell BA, Vincent A, Verkman AS, Papadopoulos MC. Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice. Brain. 2000;133:349-61.
3. Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004;364:2106-12.
4. Pandit L, Asgari N, Apiwattanakul M, Palace J, Paul F, Leite MI, et al. Demographic and clinical features of neuromyelitis optica: a review. Mult Scler. 2015;21:845-53.
5. Jarius S, Ruprecht K, Wildemann B, Kuempfel T, Ringelstein M, Geis C, et al. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients. J Neuroinflammation. 2012;9:14.
6. Nagaishi A, Takagi M, Umemura A, Tanaka M, Kitagawa Y, Matsui M, et al. Clinical features of neuromyelitis optica in a large Japanese cohort: comparison between phenotypes. J Neurol Neurosurg Psychiatry. 2011;82:1360-4.
7. Krumbholz M, Hofstadt-van Oy U, Angstwurm K, Kleiter I, Jarius S, Paul F, et al. Very late-onset neuromyelitis optica spectrum disorder beyond the age of 75. J Neurol. 2015;262:1379-84.
8. Trebst C, Jarius S, Berthele A, Paul F, Schippling S, Wildemann B, et al. Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol. 2014;261:1-16.
9. Kitley J, Leite MI, Nakashima I, Waters P, McNeillis B, Brown R, et al. Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. Brain. 2012;135:1834-49.
10. Zivkovic SA, Clemens PR, Lacomis D. Characteristics of late-onset myasthenia gravis. J Neurol. 2012;259:2167-71.
11. Titulaer MJ, McCracken L, Gabilondo I, Iizuka T, Kawachi I, Bataller L, et al. Late-onset anti-NMDA receptor encephalitis. Neurology. 2013;81:1058-63.
12. Collongues N, Marignier R, Jacob A, Leite M, Siva A, Paul F, et al. Characterization of neuromyelitis optica and neuromyelitis optica spectrum disorder patients with a late onset. Mult Scler. 2014;20:1086-94.
13. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006;66:1485-9.
14. Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol. 2007;6:805-15.
15. Li R, Qiu W, Lu Z, Dai Y, Wu A, Long Y, et al. Acute transverse myelitis in demyelinating diseases among the Chinese. J Neurol. 2011;258:2206-13.
16. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33:1444-52.
17. Pittock SJ, Weinshenker BG, Lucchinetti CF, Wingerchuk DM, Corboy JR, Lennon VA. Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol. 2006;63:964-8.
18. Kim HJ, Paul F, Lana-Peixoto MA, Tenembaum S, Asgari N, Palace J, et al. MRI characteristics of neuromyelitis optica spectrum disorder: an international update. Neurology. 2015;84:1165-73.
19. Bender BS. Infectious disease risk in the elderly. Immunol Allergy Clin North Am. 2003;23:57-64. vi.
20. Nikolich-Zugich J. The aging immune system: challenges for the 21st century. Semin Immunol. 2012;24:301-2.
21. Collongues N, Marignier R, Zephir H, Papeix C, Blanc F, Ritleng C, et al. Neuromyelitis optica in France: a multicenter study of 125 patients. Neurology. 2010;74:736-42.
22. Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85:177-89.
23. Kister I, Paul F. Pushing the boundaries of neuromyelitis optica: does antibody make the disease? Neurology. 2015;85:118-9.